1. Scrip
  2. >>R&D
  3. >>Clinical Trials

89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class

 
• By Joseph Haas

89bio’s pegozafermin met co-primary endpoints of fibrosis reduction and NASH resolution in Phase IIb; the company said its methodology yielded lower placebo responses than in Akero’s Phase IIb study.

Two racers
Competition between 89bio and Akero in NASH is tightening • Source: Shutterstock

The street hailed 89bio, Inc.’s Phase IIb top-line data readout for pegozafermin (BIO89-100) in non-alcoholic steatohepatitis (NASH) on 22 March, saying it largely levels the playing field with Akero Therapeutics, Inc. and its FGF21 analog, which yielded successful Phase IIb data last September. One analyst called the 89bio dataset “unequivocally robust and definitive PoC results,” while another asserted that the two companies’ recent data position the FGF21 class as the best “high-efficacy mechanism” in NASH.

When Akero unveiled Phase IIb data on 16 September showing that a weekly dose of efruxifermin (EFX) could both reduce...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout

 
• By Andrew McConaghie

There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.

BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory

 
• By Alaric DeArment

The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.

J&J Keeps Faith In Nipocalimab’s $5bn Sales Target Despite RA Trial Setback

 
• By Manas Mishra

Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.

DualityBio Eyes 1L Use For ADC Combos With BioNTech’s Bispecific

 
• By Dexter Jie Yan

Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.

More from R&D

Lilly’s Verzenio Scores First OS Improvement In Key Breast Cancer Setting In Decades

 
• By Alaric DeArment

The drugmaker announced topline results for the CDK4/6 inhibitor in early HR-positive, HER2-negative breast cancer, giving it a competitive edge over Novartis’s Kisqali.

Psychedelic Drug Development Shows Promise, But Market Path Remains Steep

 
• By Sushmita Panda

With late-stage trials advancing and regulatory guidance in place, psychedelic medicines are nearing a pivotal moment in their path to market. Success will hinge on overcoming clinical, logistical and commercial challenges.

Vor Unveils Positive IgAN Data For Telitacicept, But Prioritizes gMG, Sjögren’s

 
• By Alaric DeArment

A China-only Phase III study for the anti-BAFF/APRIL fusion protein marks the latest positive dataset for the drug, which Vor licensed from China-based RemeGen in June.